# Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

> **NCT01370629** · — · COMPLETED · sponsor: **Correvio International Sarl** · enrollment: 2015 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant

## Key facts

- **NCT ID:** NCT01370629
- **Lead sponsor:** Correvio International Sarl
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2018-04-05
- **Final completion:** 2018-05-08
- **Target enrollment:** 2015 (ACTUAL)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370629, "Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01370629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*